微RNA在肺癌化疗耐药中的研究进展

Progress of microRNA in chemoresistance in lung cancer

肺癌是人类常见的恶性肿瘤,化疗耐药是导致肺癌致死率上升的一个主要原因.肺癌对化疗药物产生耐药的机制尚不十分明确,大量研究表明,耐药相关基因过表达和信号转导通路异常均参与耐药.微小RNA（miRNA）是一类内源性的非编码小分子RNA,与细胞生长、凋亡和信号转导有密切关系.同时,药物在体内的代谢也可由miRNA来调节.在肿瘤细胞产生耐药过程中,miRNA也发挥着重要作用.文章就miRNA作为肺癌治疗疗效及临床预后的生物学标志物进行综述.

Lung cancer has become one of common malignant tumors, and an increasing mortality of lung cancer is mainly due to induction of resistance to chemotherapeutic agents. However, the molecular mechanism of drug resistance in lung cancer remains poorly understood. Many studies have shown that both overexpression of drug resistance genes and dysregulation of signal pathways are involved in the drug resistance. MicroRNAs （miRNAs）, a class of endogenous non-coding small RNA molecules, are closely correlated with cell growth, apoptosis and signal transduction. Meanwhile, drug metabolism in vivo can also be regulated by miRNA. Moreover, miRNA also plays an important role in drug resistance of tumor cells. This paper will highlight the potential of miRNA as suppressors and biomarkers for chemoresistance and prognosis in lung cancer.